CN110996904A - 眼用组合物及使用方法 - Google Patents

眼用组合物及使用方法 Download PDF

Info

Publication number
CN110996904A
CN110996904A CN201880043925.0A CN201880043925A CN110996904A CN 110996904 A CN110996904 A CN 110996904A CN 201880043925 A CN201880043925 A CN 201880043925A CN 110996904 A CN110996904 A CN 110996904A
Authority
CN
China
Prior art keywords
composition
eye
ophthalmic
ocular
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880043925.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·穆苏努里
S·贾因
R·阿鲁姆翰
A·乌帕德亚伊
M·努德尔
G·索马塞克哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocugen Inc
Original Assignee
Ocugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocugen Inc filed Critical Ocugen Inc
Publication of CN110996904A publication Critical patent/CN110996904A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880043925.0A 2017-05-19 2018-04-05 眼用组合物及使用方法 Pending CN110996904A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762509015P 2017-05-19 2017-05-19
US62/509,015 2017-05-19
US201762591548P 2017-11-28 2017-11-28
US62/591,548 2017-11-28
PCT/US2018/026342 WO2018212846A1 (en) 2017-05-19 2018-04-05 Ophthalmic compositions and methods of use

Publications (1)

Publication Number Publication Date
CN110996904A true CN110996904A (zh) 2020-04-10

Family

ID=64269595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880043925.0A Pending CN110996904A (zh) 2017-05-19 2018-04-05 眼用组合物及使用方法

Country Status (5)

Country Link
US (1) US10555947B2 (https=)
EP (1) EP3624773A4 (https=)
JP (1) JP2020523406A (https=)
CN (1) CN110996904A (https=)
WO (2) WO2018212846A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645356A (zh) * 2022-11-21 2023-01-31 山东诺明康药物研究院有限公司 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230277557A1 (en) * 2017-09-25 2023-09-07 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
CA3124945A1 (en) * 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP3705114A1 (en) * 2019-03-06 2020-09-09 Avizorex Pharma, S.L. Ophthalmic composition for treating dry eye and symptoms thereof
RU2705392C1 (ru) * 2019-07-19 2019-11-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Глазная мазь на основе 6-метил-3-(тиетан-3-ил)урацила с ранозаживляющим эффектом
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
KR20230110516A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 눈 장애의 치료를 위한 화합물 및 방법
AU2022212108A1 (en) * 2021-01-28 2023-08-17 Glaukos Corporation Formulations
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US11672798B2 (en) * 2021-06-03 2023-06-13 Laboratorios Salvat, S.A. Ciprofloxacin ophthalmic topical composition for treating ocular disease
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물
IL313616A (en) 2021-12-17 2024-08-01 Aerie Pharmaceuticals Inc Ophthalmic pharmaceutical compositions and uses thereof
US20250114375A1 (en) * 2022-02-08 2025-04-10 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical composition of lifitegrast and loteprednol etabonate
WO2024028815A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent
CA3264067A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS-REDUCING AGENT

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050222110A1 (en) * 2004-03-25 2005-10-06 Bartels Stephen P Use of loteprednol etabonate for the treatment of dry eye
US20160243116A1 (en) * 2015-02-24 2016-08-25 The Board Of Trustees Of The University Of Illinois Methods and Compositions for Treating Dry Eye Disease and Other Eye Disorders
WO2017006272A1 (en) * 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property Limited Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
EP1622647B1 (en) * 2003-05-12 2009-11-25 Lantheus Medical Imaging, Inc. Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
JP2007528897A (ja) 2004-03-12 2007-10-18 メルビ ホールディングス， エルエルシー 眼表面用の潤滑剤
KR20090053892A (ko) 2006-07-25 2009-05-28 오스모티카 코프. 점안액
TWM353756U (en) * 2008-04-24 2009-04-01 zong-ren Chen Structure of treadmill
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
HUE038366T2 (hu) 2010-08-16 2018-10-29 Allergan Inc Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
US20120076738A1 (en) 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
MX346312B (es) 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
JP6197386B2 (ja) * 2012-06-08 2017-09-20 ライオン株式会社 ナノエマルション粒子を含む組成物及びその製造方法
KR102407735B1 (ko) * 2014-02-14 2022-06-10 징준 후앙 나노에멀젼 전달 시스템의 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050222110A1 (en) * 2004-03-25 2005-10-06 Bartels Stephen P Use of loteprednol etabonate for the treatment of dry eye
US20160243116A1 (en) * 2015-02-24 2016-08-25 The Board Of Trustees Of The University Of Illinois Methods and Compositions for Treating Dry Eye Disease and Other Eye Disorders
US9597328B2 (en) * 2015-02-24 2017-03-21 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
WO2017006272A1 (en) * 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property Limited Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645356A (zh) * 2022-11-21 2023-01-31 山东诺明康药物研究院有限公司 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用

Also Published As

Publication number Publication date
US20180333414A1 (en) 2018-11-22
WO2018212955A1 (en) 2018-11-22
US10555947B2 (en) 2020-02-11
JP2020523406A (ja) 2020-08-06
WO2018212846A1 (en) 2018-11-22
EP3624773A4 (en) 2021-04-07
EP3624773A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
US10555947B2 (en) Ophthalmic compositions and methods of use
US11052095B2 (en) D2O stabilized pharmaceutical formulations
US20190008920A1 (en) Ophthalmic compositions and methods of use
US10154959B1 (en) Ophthalmic composition containing a polyaphron dispersion
EP3261620B1 (en) Methods and compositions for treating dry eye disease and other eye disorders
US9006214B2 (en) Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
US11759472B2 (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
WO2010059894A1 (en) Ocular formulations of norketotifen
US12350277B2 (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US10751337B2 (en) Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders
EP3843721A1 (en) Ophthalmic compositions and methods of use
JP2020527591A (ja) 活性薬剤送達のための微粒子製剤
WO2021240376A2 (en) Ophthalmic nanoemulsion compositions
US20180333357A1 (en) Nanoemulsions with anti-inflammatory activity
WO2020240451A1 (en) In-situ gelling nanoemulsion of brinzolamide
CA3115664C (en) Ophthalmic compositions and methods of use
US20180221278A1 (en) Prsustained release opthalmic formuation and methods for using the same
WO2023152644A1 (en) Pharmaceutical composition of lifitegrast and loteprednol etabonate
US9877964B2 (en) Methods and compositions for treating dry eye disease and other eye disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410

WD01 Invention patent application deemed withdrawn after publication